Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Cymbopogon schoenanthus ethanol extract** is a non-approved botanical research extract prepared from *Cymbopogon schoenanthus*, a lemongrass species. It is a complex phytochemical mixture rather than a single defined active pharmaceutical ingredient, with reported constituents including tannins, saponins, flavonoids, alkaloids, triterpenes, steroids, volatile oils, and terpene-rich fractions. Preclinical studies have investigated it for antistress and antidepressant-like effects, nephroprotective activity in kidney stone models, anti-obesity effects, antimicrobial activity, and in vitro anticancer activity. Its pharmacology appears pleiotropic and incompletely defined; reported biological effects include modulation of heat shock proteins such as HSP27 and HSP90, effects on corticosterone and catecholamine signaling, regulation of lipogenic and thermogenic proteins including UCP1, and possible anticancer activity linked to terpene constituents with in silico affinity for Polo-like kinase 1. There is no evidence in the provided context of formal clinical development, regulatory approval, or commercialization by a pharmaceutical company.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cymbopogon schoenanthus ethanol extract.